Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.190
-0.070 (-5.56%)
At close: May 18, 2026, 4:00 PM EDT
1.240
+0.050 (4.20%)
After-hours: May 18, 2026, 4:55 PM EDT

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.838.110.012.370.020.01
Research & Development
2.572.442.241.570.830.13
Total Operating Expenses
9.3910.5412.243.940.850.14
Operating Income
-9.39-10.54-12.24-3.94-0.85-0.14
Interest Income
0.170.130.05---
Interest Expense
-0--4.34-1.64--
Other Non-Operating Income (Expense)
0.05---7.49--
Total Non-Operating Income (Expense)
0.220.13-4.29-9.13--
Pretax Income
-9.17-10.41-16.53-13.07-0.85-0.14
Net Income
-9.22-10.41-16.53-13.07-0.85-0.14
Net Income to Common
-9.22-10.41-16.53-13.07-0.85-0.14
Shares Outstanding (Basic)
33323027273
Shares Outstanding (Diluted)
33323027273
Shares Change (YoY)
9.81%7.16%8.18%1.77%973.17%-
EPS (Basic)
-0.29-0.33-0.560.48-0.03-0.01
EPS (Diluted)
-0.29-0.33-0.560.48-0.03-0.01
Shares Outstanding
34.3834.3829.7628.6126.8326.83
Free Cash Flow
-5.52-3.69-5.07-3.86-0.47-0.12
Free Cash Flow Per Share
-0.17-0.12-0.17-0.14-0.02-0.05
EBITDA
-9.39-10.54-12.24-3.94-0.85-0.14
EBIT
-9.39-10.54-12.24-3.94-0.85-0.14
Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q